Trial Profile
Efficacy and Tolerability of Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children: a Comparative Study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Oct 2018
Price :
$35
*
At a glance
- Drugs Fesoterodine (Primary) ; Oxybutynin
- Indications Overactive bladder
- Focus Adverse reactions
- Acronyms FOXY
- 09 Oct 2018 Status changed from recruiting to completed.
- 16 Jun 2018 Planned End Date changed from 1 Mar 2018 to 1 Aug 2018.
- 01 Nov 2017 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.